Inovio Pharmaceuticals(US:INO) Globenewswire·2026-02-14 12:33Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. related to alleged violations of federal securities laws, particularly concerning misleading statements about the company's manufacturing and regulatory processes for its INO-3107 treatment [3][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Inovio to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Inovio, with a deadline of April 7, 2026, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Inovio and its executives made false statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [5]. Group 2: Regulatory Developments - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 but indicated that the company did not provide sufficient information for accelerated approval [6]. - Inovio announced it does not plan to pursue approval under the standard review timeline and will seek a meeting with the FDA to discuss options for accelerated approval [6]. - Following the FDA's announcement, Inovio's stock price dropped by $0.56, or 24.45%, closing at $1.73 per share [7].